Functionalized nanoparticles and methods of making and using same

Patent metadata

Field	Value
Publication number	US-12485189-B2
Application number	US-202217864671-A
Country	US
Kind code	B2
Filing date	Jul 14, 2022
Priority date	May 19, 2017
Publication date	Dec 2, 2025
Grant date	Dec 2, 2025

Abstract

Described is a versatile surface modification approach to, for example, modularly and orthogonally functionalize nanoparticles (NPs) such as, for example, PEGylated nanoparticles, ith various types of different functional ligands (functional groups) on the NP surface. It enables the synthesis of, for example, penta-functional PEGylated nanoparticles integrating a variety of properties into a single NP, e.g., fluorescence detection, specific cell targeting, radioisotope chelating/labeling, ratiometric pH sensing, and drug delivery, while the overall NP size remains, for example, below 10 nm.

First claim

The invention claimed is:

1 . A method of making a functionalized silica nanoparticle, comprising:
functionalizing silica a nanoparticle comprising polyethylene glycol (PEG) groups using a post-PEGylation surface modification by insertion (PPSMI) step, wherein the PPSMI step comprises inserting a functionalizing precursor between PEG groups on the nanoparticle and covalently binding the functionalizing precursor to the surface of the nanoparticle; and subsequently, covalently attaching a functional group to the nanoparticle by contacting the nanoparticle with a functional group precursor.

2 . The method of claim 1 , wherein the functional group precursor comprises an azide group.

3 . The method of claim 1 , wherein covalently attaching the functional group to the nanoparticle comprises a click chemistry reaction.

4 . The method of claim 1 , wherein the functional group is a targeting group or a drug.

5 . The method of claim 1 , wherein the functional group is a drug.

6 . The method of claim 5 , wherein the drug is a chemotherapeutic agent.

7 . The method of claim 1 , wherein the functional group precursor comprises a drug-linker conjugate.

8 . The method of claim 7 , wherein the linker can be cleaved by an enzyme.

9 . The method of claim 1 , wherein the functional group is a targeting group.

10 . The method of claim 9 , wherein the targeting group has a specific binding affinity to a tumor cell.

11 . The method of claim 1 , wherein the silica nanoparticle comprises one or more fluorescent dye molecules encapsulated therein.

12 . The method of claim 1 , wherein the nanoparticle has a diameter of 10 nm or less.

13 . A method of making a functionalized silica nanoparticle, comprising:
functionalizing silica a nanoparticle comprising polyethylene glycol (PEG) groups using a post-PEGylation surface modification by insertion (PPSMI) step, wherein the PPSMI step comprises inserting a functionalizing precursor between PEG groups on the nanoparticle and covalently binding the functionalizing precursor to the surface of the nanoparticle; and subsequently, covalently attaching a drug-linker conjugate to the nanoparticle by contacting the nanoparticle with a drug-linker conjugate precursor.

14 . The method of claim 13 , wherein the drug-linker conjugate precursor comprises an azide group.

15 . The method of claim 13 , wherein the drug is a chemotherapeutic agent.

16 . The method of claim 13 , wherein the linker can be cleaved by an enzyme.

17 . The method of claim 13 , further comprising covalently attaching a targeting group to the nanoparticle by contacting the nanoparticle with a functional group precursor comprising the targeting group.

18 . The method of claim 17 , wherein the targeting group has a specific binding affinity to a tumor cell.

19 . The method of claim 17 , wherein the functional group precursor comprises an azide group.

20 . The method of claim 17 , wherein covalently attaching the targeting group to the nanoparticle comprises click chemistry.

21 . The method of claim 13 , wherein the silica nanoparticle comprises one or more fluorescent dye molecules encapsulated therein.

22 . The method of claim 13 , wherein the nanoparticle has a diameter of 10 nm or less.

Assignees

• Univ Cornell

Inventors

• Ma Kai
• Wiesner Ulrich B

Classifications

• B82Y5/00

  Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery · CPC title

• A61K49/0054

  Macromolecular compounds, i.e. oligomers, polymers, dendrimers · CPC title

• A61K49/0043

  Fluorescein, used in vivo · CPC title

• A61K49/0032

  Methine dyes, e.g. cyanine dyes · CPC title

• A61K47/02

  Inorganic compounds · CPC title